# Atrium Therapeutics, Inc.: financial statements, quarterly

RNA · Nasdaq · CIK 2093101 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/rna.md) · [Financials](/companies/rna/financials.md) · [Filings](/companies/rna/filings.md) · [Insiders](/companies/rna/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/rna/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Revenue | $m | [1.6](/filings/0001193125-26-224243.md) | [3.8](/filings/0001193125-26-349488.md) | [19.6](/filings/0001193125-26-224243.md) | [3.0](/filings/0001193125-26-349488.md) |
| Research and development | $m | [6.9](/filings/0001193125-26-224243.md) | [13.3](/filings/0001193125-26-349488.md) | [16.7](/filings/0001193125-26-224243.md) | [15.3](/filings/0001193125-26-349488.md) |
| Operating income | $m | [(7.5)](/filings/0001193125-26-224243.md) | [(12.9)](/filings/0001193125-26-349488.md) | [(17.3)](/filings/0001193125-26-224243.md) | [(22.6)](/filings/0001193125-26-349488.md) |
| Net income | $m | [(7.4)](/filings/0001193125-26-349488.md) | [(12.9)](/filings/0001193125-26-349488.md) | [(16.6)](/filings/0001193125-26-349488.md) | [(20.2)](/filings/0001193125-26-349488.md) |
| Diluted EPS | $ per share | [(0.44)](/filings/0001193125-26-224243.md) | [(0.75)](/filings/0001193125-26-349488.md) | [(0.97)](/filings/0001193125-26-224243.md) | [(1.18)](/filings/0001193125-26-349488.md) |
| Basic EPS | $ per share | [(0.44)](/filings/0001193125-26-224243.md) | [(0.75)](/filings/0001193125-26-349488.md) | [(0.97)](/filings/0001193125-26-224243.md) | [(1.18)](/filings/0001193125-26-349488.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2024-12-31) | period not labelled (2025-03-31) | period not labelled (2025-06-30) | period not labelled (2025-12-31) | period not labelled (2026-02-26) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | [0.0](/filings/0001193125-26-224243.md) | [0.0](/filings/0001193125-26-349488.md) | [0.0](/filings/0001193125-26-349488.md) | [270](/filings/0001193125-26-349488.md) | [268](/filings/0001193125-26-224243.md) | [72.3](/filings/0001193125-26-349488.md) |
| Current assets | $m | not reported | not reported | not reported | [2.8](/filings/0001193125-26-349488.md) | not reported | [286](/filings/0001193125-26-224243.md) | [275](/filings/0001193125-26-349488.md) |
| Total assets | $m | not reported | not reported | not reported | [8.4](/filings/0001193125-26-349488.md) | not reported | [292](/filings/0001193125-26-224243.md) | [281](/filings/0001193125-26-349488.md) |
| Current liabilities | $m | not reported | not reported | not reported | [41.8](/filings/0001193125-26-349488.md) | not reported | [21.9](/filings/0001193125-26-224243.md) | [31.5](/filings/0001193125-26-349488.md) |
| Total liabilities | $m | not reported | not reported | not reported | [71.1](/filings/0001193125-26-349488.md) | not reported | [58.3](/filings/0001193125-26-224243.md) | [65.9](/filings/0001193125-26-349488.md) |
| Shareholders' equity | $m | [(61.1)](/filings/0001193125-26-224243.md) | [(56.3)](/filings/0001193125-26-349488.md) | [(56.2)](/filings/0001193125-26-349488.md) | [(62.7)](/filings/0001193125-26-349488.md) | not reported | [234](/filings/0001193125-26-349488.md) | [215](/filings/0001193125-26-349488.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(11.1)](/filings/0001193125-26-224243.md) | [(11.9) d](/filings/0001193125-26-349488.md) | [(31.1)](/filings/0001193125-26-224243.md) | [(3.9) d](/filings/0001193125-26-349488.md) |
| Capital expenditure | $m | [0.0](/filings/0001193125-26-224243.md) | [0.3 d](/filings/0001193125-26-349488.md) | [2.1](/filings/0001193125-26-224243.md) | [0.0 d](/filings/0001193125-26-349488.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [17.1](/filings/0001193125-26-224243.md) | [17.1](/filings/0001193125-26-349488.md) | [17.1](/filings/0001193125-26-224243.md) | [17.1](/filings/0001193125-26-349488.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 17,105,643 at 2026-08-03, from the cover of the [10-Q filed 2026-08-13](/filings/0001193125-26-349488.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:51 ET. No prices; not investment advice.